Key Drivers
- Cash Buffer
- No Revenue
- Persistent Losses
AIAI Summary
OLMA should now be viewed as a cash-backed but highly binary catalyst play, with the investment case hinging almost entirely on a clean Q1 2027 OPERA-01 readout while the main near-term risks are a long catalyst wait, persistent losses, and potential dilution if management seeks added flexibility before data.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Buffer
- •No Revenue
- •Persistent Losses
OLMA has an exceptionally strong cash-rich balance sheet, but the lack of revenue, continued large losses, and ongoing cash burn outweigh that strength and keep the investment case highly speculative.
Price Behavior
Key Price Behavior Insights:
- •Broken range
- •Support defense
- •Weak momentum
Over the last month, OLMA remains in a short-term downtrend after breaking from $12.05 to $10.43, with buyers defending $10.43–$10.51 but a real recovery still needing a move back above $11.80–$12.05.
Sharp drop from $12.05 on 2026-08-07 to $10.43 on 2026-08-11 broke the prior trading band
Sentiment & News
Key News Insights:
- •Phase 3 enrollment
- •Data pushed out
- •Employee hiring
Olema Oncology completed enrollment in its pivotal OPERA-01 Phase 3 breast cancer trial, but the shift of top-line data to Q1 2027 tempered sentiment even as the company added staff with equity grants.
Completing enrollment is a meaningful clinical milestone, but the delayed readout may keep the stock range-bound until results emerge
Similar Companies in Healthcare
Other companies in the same sector with AI ratings